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To the Editor: We read with great interest the report by
Cooper et al. [1] on unblinded treatment for left-ventricular
hypertrophy in type 2 diabetes patients using triethylene-
tetramine for chelation of copper vs placebo. The results are
very promising and certainly merit independent confirma-
tion in larger double-blind, placebo-controlled trials. The
authors should be commended for their detailed description
of measurement of the primary endpoint of their study, left-
ventricular mass by magnetic resonance imaging. However,
the authors did not provide information on the way they
measured serum copper or urinary copper excretion. Such
information would be of interest for future trials and
comparison of obtained results. It would also be of interest
if the authors could discuss the seeming discrepancy
between their conclusion that copper excretion fell to
placebo levels after 12 months of treatment, while mean
values shown in Fig. 2b of their article seem to plateau at
approximately 6 times those of placebo after 10 and
12 months of treatment, with the difference at 10 months
of treatment still highly significant. It seems that the non-
significance of the p value at 12 months of treatment could
be the consequence of loss of statistical power for
comparison rather than of a decline in copper excretion
between 10 and 12 months of treatment. In their report, the
authors state that during the last 6 months of the study, five
patients discontinued triethylenetetramine and one patient
discontinued placebo. To effectively judge statistical power
at 10 vs 12 months of treatment, it would be important to
know how many patients discontinued during the last
2 months of the study. This is important because the authors
suggested that triethylenetetramine only leads to excretion
of ‘excess’ copper, without threat of deficiency [1], while
ongoing copper loss could lead to copper deficiency with
risk of anaemia, pancytopenia and neurodegeneration [2, 3].
Another relevant point concerning the statistical analyses is
that the copper values appeared to be highly skewed, in
which case it would be more appropriate to report trans-
formed values and use non-parametric statistics.
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